What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?

All the amyloid antibody trials were conducted in patients without the burden of cerebrovascular disease we often see in clinic populations. Many individuals with cognitive impairment have both vascular and neurogenerative contributions to their decline. We don’t yet know from real-world experience ...

Lecanemab and donanemab were studied in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Confirmation with biomarkers and exclusion of other possible causes of dementia is required.